DEF 14A: BranchOut Food Inc. Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting

Sentiment:

Definitive Proxy Statement


BranchOut Food Inc. is holding its 2024 Annual Meeting of Stockholders on October 14, 2024, to vote on the election of directors, approval of a convertible note and warrants, executive compensation, and other matters.

Capital raiseThe company issued a 12% Senior Secured Convertible Promissory Note in the principal amount of up to $3,400,000 to Kaufman Kapital LLC on July 24, 2024.The company issued warrants to purchase an aggregate of 1,500,000 shares of common stock to Kaufman Kapital LLC on July 24, 2024.The company issued warrants to purchase an aggregate of 865,536 shares of common stock in a private placement to three investors, consisting of Eric Healy, John Dalfonsi, and the company's President.
Worse than expectedThe company was not in compliance with Nasdaq Listing Rule 5550(b)(1) because its stockholders equity of $2,210,476 as of December 31, 2023 was below the minimum requirement of $2,500,000.

Summary

  • BranchOut Food Inc. is convening its Annual Meeting of Stockholders on October 14, 2024, to address several key proposals.
  • Stockholders will vote on the election of six directors, the approval of the conversion of a $3,400,000 convertible promissory note issued to Kaufman Kapital LLC, and the approval of the exercise of warrants issued to Kaufman and company affiliates.
  • Additionally, stockholders will cast advisory votes on executive compensation and the frequency of such votes, as well as ratify the appointment of M&K CPAS, PLLC as the company's independent registered public accountants for the fiscal year ending December 31, 2024.
  • The Board of Directors recommends voting in favor of all proposals.
  • The record date for determining stockholders eligible to vote is September 6, 2024.
  • The proxy materials were made available on or about September 10, 2024.

Sentiment

Score: 5

Explanation: The document is primarily informational, outlining the proposals to be voted on at the annual meeting. While the company is seeking approval for financing transactions, which could be viewed positively, the potential dilution and impact on stock price temper the overall sentiment.

Positives

  • The conversion of the Convertible Note would free up cash that the Company would otherwise have been required to use to repay amounts outstanding under the Convertible Note.
  • Conversion of the Convertible Note and exercise of warrants could help the company regain or maintain compliance with Nasdaq listing requirements regarding stockholders' equity.

Negatives

  • Approval of the proposals related to the convertible note and warrants could result in significant dilution of existing stockholders' ownership.
  • The sale of shares issued upon conversion or exercise of warrants could negatively impact the market price of the company's common stock.

Risks

  • Failure to obtain stockholder approval for the proposals could impact the company's ability to secure additional funding and maintain Nasdaq listing compliance.
  • The potential issuance of a large number of shares could dilute existing stockholders and depress the stock price.
  • The company's obligations under the Convertible Note are secured by a lien granted to Kaufman on substantially all of the Company's assets.

Future Outlook

The company seeks to obtain stockholder approval for key proposals to facilitate financing and maintain Nasdaq compliance.

Management Comments

  • The Board of Directors unanimously recommends that the stockholders vote FOR the election of the six nominated directors.
  • The Board of Directors unanimously recommends that stockholders vote FOR the proposal to approve the conversion in full of the Convertible Note.
  • The Board of Directors unanimously recommends that stockholders vote FOR the proposal to approve the exercise in full of the Kaufman Warrants.
  • The Board of Directors unanimously recommends that stockholders vote FOR the proposal to approve the exercise in full of the Investor Warrants.
  • The Board of Directors unanimously recommends that stockholders vote FOR the proposal to approve the compensation of our named executive officers.
  • The Board of Directors recommends that stockholders vote FOR every year as the frequency with which stockholders are provided an advisory vote on executive compensation.
  • The Board of Directors unanimously recommends that stockholders vote FOR the ratification of the selection of M&K CPAS, PLLC as the Company's independent registered public accountants for the year ending December 31, 2024.

Industry Context

The proposals reflect the company's efforts to secure funding and maintain compliance with Nasdaq listing requirements, which are common challenges for publicly traded companies, especially smaller ones.

Comparison to Industry Standards

  • Seeking stockholder approval for dilutive financing transactions is a standard practice for companies listed on exchanges like Nasdaq.
  • The terms of the convertible note and warrants, including interest rates and exercise prices, appear to be within the range of similar financing instruments for companies of comparable size and risk profile.
  • Executive compensation practices are subject to increasing scrutiny, and advisory votes on executive pay have become a common feature of corporate governance.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Financial OfficerDouglas DurstJohn DalfonsiJanuary 10, 2024Douglas Durst was CFO until August 14, 2023, Chris Coulter was CFO from August 14, 2023 until January 10, 2024, and John Dalfonsi was appointed on January 10, 2024.

Related Party Transactions

  • Eric Healy, John Dalfonsi, and Christopher Coulter purchased Units from the Company.
  • Byron Rich Jones held a convertible note that was converted into common stock.
  • Tom Healy and Carol Healy (CEO's parents) held a convertible note that was converted into common stock.
  • Fluffco, LLC held convertible notes that were converted into common stock.
  • Don Foss held a convertible note that was converted into common stock.
  • Eagle Vision provided consulting services to the Company and received warrants as compensation.

Stakeholder Impact

  • Stockholders face potential dilution from the conversion of the convertible note and exercise of warrants.
  • Employees may be impacted by the company's ability to secure funding and execute its business plan.
  • The company's financial stability and future prospects could affect its relationships with customers, suppliers, and creditors.

Next Steps

  • Stockholders need to vote on the proposals outlined in the proxy statement.
  • The company will hold its Annual Meeting of Stockholders on October 14, 2024.
  • The company will file a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose the voting results.

Key Dates

DateDescription
August 14, 2022Date of The Donald A. Foss Irrevocable Living Trust
December 6, 2022Date of employment agreement with CEO Eric Healy
April 12, 2022Date of consulting agreement with Eagle Vision
June 21, 2023John Dalfonsi appointed as director
January 10, 2024John Dalfonsi appointed as CFO; Byron Rich Jones appointed to Board and audit committee chair
July 15, 2024Date of Securities Purchase Agreement with Kaufman Kapital LLC and Subscription Agreements with investors
July 24, 2024Issuance of Convertible Note and Warrants to Kaufman Kapital LLC; Deven Jain appointed to Board of Directors
September 6, 2024Record date for Annual Meeting
September 10, 2024Date of Proxy Statement
October 13, 2024Deadline for proxy card receipt by mail
October 14, 2024Annual Meeting of Stockholders
May 13, 2025Deadline for stockholder proposals for 2025 Annual Meeting
December 31, 2025Maturity date of Convertible Note and expiration date of Kaufman Warrants

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Convertible Note, Warrants, Executive Compensation, M&K CPAS, Kaufman Kapital, Director Election, Nasdaq Listing Rules

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.